AUTHORS
Aniket Bankar, MD, MSc, DM, MBBS, Andrew T Kuykendall, MD2, Kristen Pettit, MD3, Joseph Shatzel, MD4, Jiri Mayer, MD5, Valentín García Gutiérrez I, MD6, Alessandro Lucchesi, MD, PhD7, Naveen Pemmaraju, MD8, Abdulraheem Yacoub, MD9, Harinder Gill, MBBS, MD10, Daniel Sasca, MD11, David M. Ross, MBBS, PhD12, Maria Laura Fox, MD13, Arturo Molina, MD, MS14, Phil Dinh15, Xuzhi Wang16, Alisa Harrigan17, Shining Wang, MD, PhD18, Alessandro Vannucchi, MD19
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Moffitt Cancer Center, Tampa, Florida, United States
3 University of Michigan, Ann Arbor, Michigan, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 University Hospital Brno and Masaryk University, Brno, Czech Republic
6 Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
7 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Kansas Cancer Center, Westwood, Kansas, United States
10 Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, Hong Kong
11 University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
12 Royal Adelaide Hospital, Adelaide, South Australia, Australia
13 Hospital Universitario Vall d'Hebron, Barcelona, Spain
14 Protagonist Therapeutics, Inc., Newark, California, United States
15 Protagonist Therapeutics, Inc., Newark, California, United States
16 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
17 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
18 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
19 Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
ABSTRACT
Introduction: Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by erythrocytosis, elevated hematocrit (Hct), and increased blood viscosity, which increases the risk of life-threatening thromboembolic events (TEs). TE risk is greater in patients (pts) who have had a prior TE and/or are aged ≥60 years (yrs). Current standard of care aims to maintain Hct <45% and includes phlebotomy (PHL) with/without cytoreductive therapy (CRT). In the phase 3 VERIFY study (NCT05210790), rusfertide, a first-in-class, self-administered subcutaneous peptide that regulates iron homeostasis by mimicking the endogenous hormone hepcidin, met the primary endpoint of clinical response (absence of PHL eligibility) vs placebo (PBO). Given the clinical importance of age in PV, and United States payer considerations (Medicare and commercial) based on age ≥65 years, this post hoc analysis assessed efficacy and safety of rusfertide vs PBO in pts aged ≥65 and <65 yrs in VERIFY, to determine whether treatment effects were consistent across age groups.
Methods: Pts with PV requiring PHL to maintain Hct <45% were randomized 1:1 to receive once weekly rusfertide or PBO, in addition to ongoing PV therapy (PHL with/without CRT for 32 weeks [Wks; part 1a]); stratified by ongoing PV therapy. The primary endpoint was the proportion of pts achieving clinical response (absence of PHL eligibility) from Wks 20 to 32. Key secondary endpoints were mean number of PHLs, proportion of pts with Hct <45%, and mean score change from baseline to Wk 32 in patient-reported outcome questionnaires: Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue short form-8a T-Score and Myelofibrosis Symptom Assessment Form Total Symptom Score 7 (MFSAF TSS7) version 4.0. Safety endpoints included treatment-emergent adverse events (TEAEs) in each age group.
Results:
At data cut-off (May 27, 2025), 293 pts were randomized, 147 to rusfertide and 146 to PBO. At baseline, 75 pts (25.6%) were ≥65 yrs old and 218 pts (74.4%) were <65 yrs old. During Wks 20–32, more rusfertide-treated pts achieved clinical response vs PBO among pts aged ≥65 yrs: 70.0% vs 28.6%, respectively (P=0.0003) and <65 yrs: 79.4% vs 34.2%, respectively (P<0.0001). Mean (standard deviation) number of PHLs from baseline to Wk 32 was lower with rusfertide vs PBO, respectively, regardless of age group: 0.7 (1.6) vs 2.0 (1.7) in pts aged ≥65 yrs, and 0.5 (0.9) vs 1.7 (1.4) in pts <65 yrs. A significantly higher number of pts maintained Hct <45% with rusfertide vs PBO, respectively, between Wks 0 and 32, regardless of age group: 62.5% vs 14.3% (P<0.0001) in pts aged ≥65 yrs and 62.6% vs 14.4% (P<0.0001) in pts <65 yrs.
PROMIS Fatigue T-score changes from baseline to Wk 32 numerically favored rusfertide vs PBO in both age groups, with least square (LS) mean (standard error [SE]) differences of -4.1 (1.7; P=0.0154) in pts aged ≥65 yrs and -1.5 (1.0; P=0.1564) in pts aged <65 yrs. At Wk 32, reductions (improvements) in MFSAF TSS7 numerically favored rusfertide vs PBO in both age groups, with LS mean (SE) differences of −1.1 (1.3; P=0.4081) in pts aged ≥65 yrs and −2.1 (1.0; P=0.0377) in pts <65 yrs.
Among pts aged ≥65 yrs (n=74), TEAEs with rusfertide vs PBO, respectively, occurred in 87.2% vs 88.6% of pts and treatment-related TEAEs in 64.1% vs 45.7%. Among pts aged <65 yrs (n=217), TEAEs were reported in 91.5% vs 85.6% of pts and treatment-related TEAEs in 72.6% vs 53.2% of pts with rusfertide vs PBO, respectively. Among pts aged ≥65 yrs, TEAEs occurring in ≥15% of patients with rusfertide vs PBO, respectively, were anemia (15.4% vs 2.9%), injection site erythema (28.2% vs 5.7%), fatigue (17.9% vs 20.0%), injection site pruritus (17.9% vs 0%), dizziness (15.4% vs 0%), constipation (12.8% vs 17.1%), and arthralgia (0% vs 20.0%); among pts aged <65 yrs, corresponding TEAEs were injection site erythema (34.9% vs 7.2%), anemia (15.1% vs 4.5%), fatigue (15.1% vs 14.4%), injection site pain (19.8% vs 17.1%), and injection site pruritus (17.9% vs 2.7%).
Conclusions: In this post hoc analysis of the VERIFY study, rusfertide demonstrated consistent efficacy in pts aged ≥65 and <65 yrs. The safety profile was comparable between age groups, with no age-specific safety signals identified. These findings highlight the efficacy and tolerability of rusfertide in pts with PHL-dependent PV, regardless of age.
DISCLOSURES
Aniket Bankar, MD, MSc, DM, MBBS: Takeda - Honoraria; Protagonist - Research Funding; Forus Therapeutics - Consultancy (Includes expert testimony)